Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02474433
Other study ID # 0083-15-WOMC
Secondary ID
Status Recruiting
Phase Phase 4
First received June 14, 2015
Last updated April 28, 2016
Start date July 2015
Est. completion date July 2017

Study information

Verified date April 2016
Source Wolfson Medical Center
Contact Hadas Ganer Herman, MD
Phone 972526206696
Email hadassganer@yahoo.com
Is FDA regulated No
Health authority Israel: Ethics Commission
Study type Interventional

Clinical Trial Summary

This is a randomized trial, assessing Misoprostol efficacy in cervical preparation several hours prior to hysteroscopy, comparing the different routes of administration (PO/PV/buccal). Initial cervical dilatation will be assessed, as well as surgical ease of dilatation, time required to achieve dilatation and patient preference.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date July 2017
Est. primary completion date July 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients admitted for elective hysteroscopy (diagnostic/surgical) at Wolfson Medical Center

- Written consent supplied

Exclusion Criteria:

- Contraindications to prostaglandin treatment (severe asthma, glaucoma, severe cardiac disease, renal failure)

- Prostaglandin allergy

- Pregnancy

- Genital infection

- Space-occupying lesion in the endocervical canal

- Prior cervical surgery

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Prevention


Related Conditions & MeSH terms

  • Cervical Preparation Prior to Hysteroscopy

Intervention

Drug:
Misoprostol (Cytotec)


Locations

Country Name City State
Israel Edith Wolfson Medical Center Holon

Sponsors (1)

Lead Sponsor Collaborator
Wolfson Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Preoperative cervical width in centimeters Initial cervical dilatation assessed by performing cervical dilatation , beginning with a number 10 Hegar dilator and subsequently inserting smaller Hegar dilators until the dilator can pass through the internal os without resistance. The largest one to pass will consist the initial cervical width. intraoperative No
Secondary Time required to achieve cervical dilatation The time in minutes required for dilatation up to a number 10 Hegar intraoperative No
Secondary Ease of cervical dilatation The subjective ease of cervical dilatation recorded by the surgeon on a 5-point Likert scale (1-very difficult, 5- very easy) intraoperative No
Secondary Patient preference Patient acceptability of the administration of medication on a 5-point Likert scale (1-very uncomfortable, 5-very comfortable) baseline No
Secondary Adverse effects of medication Self reported misoprostol-associated adverse effects before the procedure (such as nausea, vomiting) baseline No
Secondary Surgical complications Complications arising during surgery (perforation, cervical laceration, excess bleeding) intraoperative No